Stem Cell Clinical Trials

3 recruiting

Frequently Asked Questions

Common questions about Stem Cell clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 140 trials

Recruiting

Long-Term Follow-up of People Undergoing Hematopoietic Stem Cell Transplantation

Hematopoietic Stem Cell TransplantationTissue Donors
National Cancer Institute (NCI)2,000 enrolled1 locationNCT03000244
Recruiting
Phase 2

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

Hematopoietic Stem Cell TransplantationImmunodeficiency
National Cancer Institute (NCI)54 enrolled1 locationNCT05027945
Recruiting
Not Applicable

Safety, Tolerability, and Efficacy of Enteral Nutrition Versus Standard of Care Nutrition in Hematopoietic Stem Cell Transplant Patients: A Pilot Study

Stem Cell
M.D. Anderson Cancer Center40 enrolled1 locationNCT06004063
Recruiting
Early Phase 1

Secretome Treatment for Facial Rejuvenation

Stem CellFacial AgingRejuvenation+1 more
Acorn Biolabs Inc.24 enrolled1 locationNCT07227883
Recruiting
Not Applicable

Psychosocial and Behavioral Intervention for Stem Cell Transplant Patients and Their Family Caregivers

Stem Cell TransplantHematopoetic Stem Cell TransplantationHematopoetic Stem Cell Transplant
University of Pittsburgh208 enrolled1 locationNCT07107165
Recruiting
Not Applicable

Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation

Hematologic DisordersPatients With Hematologic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation
The General Hospital of Western Theater Command45 enrolled1 locationNCT07483385
Recruiting

Early Detection of Infectious and Noninfectious Lung Diseases Following Allogeneic Hematopoietic Stem Cell Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
National Heart, Lung, and Blood Institute (NHLBI)40 enrolled1 locationNCT06093867
Recruiting
Phase 2

Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies

Allogeneic Stem Cell Transplant Recipient
Hackensack Meridian Health209 enrolled3 locationsNCT07214688
Recruiting
Phase 1Phase 2

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Hematopoietic Stem Cell TransplantationPeripheral Blood Stem Cell Transplantation
National Cancer Institute (NCI)260 enrolled2 locationsNCT05436418
Recruiting
Not Applicable

Longitudinal Early Advance Care Planning Discussions and Documentation (LEADD) Program: An Exploratory Study in Adolescents and Young Adults (AYAs) Receiving Hematopoietic Stem Cell Transplant

Hematopoietic Stem Cell Transplantation
National Cancer Institute (NCI)222 enrolled2 locationsNCT05605574
Recruiting
Phase 4

Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Chinese PLA General Hospital200 enrolled1 locationNCT07101588
Recruiting

Nutritional Status of Patients After Hematopoietic Stem Cell Transplantation

Hematopoietic Stem Cell TransplantationNutrition
The First Affiliated Hospital of Soochow University200 enrolled1 locationNCT04146870
Recruiting
Phase 2

Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaTransplantation, Stem Cell+1 more
The First Affiliated Hospital of Soochow University48 enrolled1 locationNCT06816134
Recruiting
Not Applicable

A Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors

Sexual DysfunctionStem Cell Transplant ComplicationsBone Marrow Transplant Complications
Massachusetts General Hospital300 enrolled3 locationsNCT06541002
Recruiting
Phase 3

Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial

VenentoclaxALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONMyeloid Malignancies+3 more
First Affiliated Hospital of Zhejiang University186 enrolled18 locationsNCT07396480
Recruiting
Phase 1Phase 2

Immune Tolerance Induction After Liver Transplantation

Liver TransplantationEnd Stage Liver DiseaseImmune Tolerance+6 more
University of California, Los Angeles12 enrolled1 locationNCT07269041
Recruiting
Not Applicable

Moxibustion for the Prevention of Hemorrhagic Cystitis After Allo-HSCT

PreventionHematopoietic Stem Cell TransplantationHemorrhagic Cystitis+1 more
Yi Zhang266 enrolled4 locationsNCT06198517
Recruiting
Phase 2

Ivosidenib as Post-HSCT Maintenance for AML

Acute Myeloid Leukemia (AML)IDH1 MutationHematopoietic Stem Cell Transplant (HSCT)
Massachusetts General Hospital75 enrolled3 locationsNCT06707493
Recruiting
Not Applicable

Supportive Care Intervention for Outpatient Stem Cell Transplant Patients

CancerHematopoietic Stem Cell Transplantation
Victor Wang90 enrolled1 locationNCT06564233
Recruiting
Phase 3

Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT

ThrombocytopeniaHematopoietic Stem Cell Transplantation
First Affiliated Hospital of Zhejiang University404 enrolled1 locationNCT07442513